Stop Addiction Stigma

NCT06582030 | Completed

• 2 other identifiers: OSU-23194NCI-2024-04797
• Study Type: interventional
• Target: 93
• Locations: 1 country
• Sites: 1

Brief Summary

This clinical trial evaluates the impact of a Stop Addiction Stigma (SAS) training workshop with a short description of the conditions related to addiction (vignettes) on stigmatizing attitudes toward individuals with substance abuse disorders. Reviews have shown that patients with substance abuse disorders have experienced negative attitudes from their health care providers. Negative attitudes may lead to less involvement from the provider and the patient and may lead to less effective care. Using case vignettes with a SAS workshop may be an effective method to help people learn about addiction, reduce the stigma toward addiction and improve the quality of health care.

Conditions

Hematopoietic and Lymphatic System Neoplasm; Malignant Solid Neoplasm

Outcome Measures

Primary Outcomes (1)

• Stigmatizing attitudes

  Stigmatizing attitudes will be measured with the Stigma and Attribution Assessment. The assessment score will be compared both between and within participants for each case vignette. Results will be reported with descriptive statistics, including means and standard deviations or medians and first-third quartiles for continuous variables, and frequencies and percentages for discrete variables.The linear mixed effect model will be used to study the repeated stigma and attribution measures over time (pre-workshop, immediately post-workshop, and 8 weeks post-workshop) within 6 vignettes as well as the effects between the vignettes, while controlling for the potential confounding factors (e.g., sex).

  Before, immediately after and 8 weeks after the session

Secondary Outcomes (2)

• Attendance rate

  At 90 minute session.

• Response to post-workshop evaluations

  Before, immediately following and 8 weeks after the session.

Study Arms (6)

Group A (chronically relapsing brain disease vignette, SAS)

EXPERIMENTAL

Participants view the chronically relapsing brain disease vignette and attend a SAS workshop on study.

Behavioral: Assessment; Other: Educational Activity

Group B (brain disease vignette, SAS)

EXPERIMENTAL

Participants view the brain disease vignette and attend a SAS workshop on study.

Behavioral: Assessment; Other: Educational Activity; Other: Training

Group C (disease vignette, SAS)

EXPERIMENTAL

Participants view the disease vignette and attend a SAS workshop on study.

Behavioral: Assessment; Other: Educational Activity; Other: Training

Group D (illness vignette, SAS)

EXPERIMENTAL

Participants view the illness vignette and attend a SAS workshop on study.

Behavioral: Assessment; Other: Educational Activity; Other: Training

Group E (disorder vignette, SAS)

EXPERIMENTAL

Participants view the disorder vignette and attend a SAS workshop on study.

Behavioral: Assessment; Other: Educational Activity; Other: Training

Group F (problem vignette, SAS)

EXPERIMENTAL

Participants view the problem vignette and attend a SAS workshop on study.

Behavioral: Assessment; Other: Educational Activity; Other: Training

Interventions

Assessment BEHAVIORAL

Ancillary studies

Also known as: Assess, Study Assessment, Study Observation

Group A (chronically relapsing brain disease vignette, SAS); Group B (brain disease vignette, SAS); Group C (disease vignette, SAS); Group D (illness vignette, SAS); Group E (disorder vignette, SAS); Group F (problem vignette, SAS)

Educational Activity OTHER

View the chronically relapsing brain disease vignette

Group A (chronically relapsing brain disease vignette, SAS)

Training OTHER

Attend a SAS workshop

Also known as: Training Programs

Group B (brain disease vignette, SAS); Group C (disease vignette, SAS); Group D (illness vignette, SAS); Group E (disorder vignette, SAS); Group F (problem vignette, SAS)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Employee of Ohio State University Wexner Medical Center (OSUWMC)
• Age ≥ 18 years
• Participants must be able to read and comprehend survey items

Sponsors & Collaborators

• Ohio State University Comprehensive Cancer Center: lead

Study Sites (1)

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States

Location

Related Links

• The Jamesline

MeSH Terms

Interventions

Restraint, Physical; Outcome Assessment, Health Care; Observational Studies as Topic; Resistance Training

Intervention Hierarchy (Ancestors)

Behavior Control; Therapeutics; Immobilization; Investigative Techniques; Outcome and Process Assessment, Health Care; Quality of Health Care; Health Services Administration; Health Care Evaluation Mechanisms; Health Care Quality, Access, and Evaluation; Clinical Studies as Topic; Epidemiologic Study Characteristics; Epidemiologic Methods; Public Health; Environment and Public Health; Exercise Therapy; Rehabilitation; Aftercare; Continuity of Patient Care; Patient Care; Physical Therapy Modalities; Physical Conditioning, Human; Exercise; Motor Activity; Movement; Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena

Study Officials

• Gretchen A Mcnally, PhD, APRN-CNP

  Ohio State University Comprehensive Cancer Center

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: HEALTH SERVICES RESEARCH
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: June 27, 2024
• First Posted: September 3, 2024
• Study Start: October 17, 2023
• Primary Completion: December 31, 2023
• Study Completion: December 31, 2023
• Last Updated: September 3, 2024

Record last verified: 2024-08

Locations

US (1)